Evidence-Based Medicine Guidelines
Subcutaneous trepostinil for pulmonary hypertension
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Subcutaneous Trepostinil for Pulmonary Hypertension." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451286/all/Subcutaneous_trepostinil_for_pulmonary_hypertension.
Subcutaneous trepostinil for pulmonary hypertension. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/451286/all/Subcutaneous_trepostinil_for_pulmonary_hypertension. Accessed December 4, 2024.
Subcutaneous trepostinil for pulmonary hypertension. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/451286/all/Subcutaneous_trepostinil_for_pulmonary_hypertension
Subcutaneous Trepostinil for Pulmonary Hypertension [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 December 04]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451286/all/Subcutaneous_trepostinil_for_pulmonary_hypertension.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Subcutaneous trepostinil for pulmonary hypertension
ID - 451286
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451286/all/Subcutaneous_trepostinil_for_pulmonary_hypertension
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
